Republicans Ratchet Up Attacks On US FDA’s COVID Response
Executive Summary
Pair of letters that target research focus and therapeutic review speed is a potential preview of the kind of oversight that the agency may be subject to if the GOP retakes control of the House this fall.
You may also be interested in...
Aduhelm Medicare Coverage: House Republicans Push For CMS To Collaborate With US FDA
More than 70 Republican representatives object to CMS draft national coverage determination for Alzheimer’s disease drugs. They ask if CMS will treat future drugs approved under the accelerated approval pathway differently and how it will coordinate with FDA.
Culture Wars Reach Labeling For COVID-19 Treatments
Senators ask US FDA to change statements in COVID-19 monoclonal antibody fact sheets that factors like race or ethnicity may place a patient high-risk of serious illness, saying they promote racist decisions.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.